SLC16A3 and neoplasm: More importantly, Alkbh5 might affect the efficacy of immunotherapy in CRC by regulating the expression of MCT4/Slc16a3 and the composition of lactate in TME, tumor-infiltrating Treg cells and MDSC cells, which has been identified as a potential immunotherapy target (81).